A protein knockdown strategy to study the function of β-catenin in tumorigenesis

BMC Molecular Biology

Volumn 4, Issue , 2003, Pages

  Cong, Feng ^a   Zhang, Jianxuan ^b   Pao, William ^a   Zhou, Pengbo ^b   Varmus, Harold ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CHIMERIC PROTEIN; CYCLIN D; MYC PROTEIN; UBIQUITIN PROTEIN LIGASE; UVOMORULIN; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL FATE; CELL GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COLON CANCER; COLON POLYPOSIS; CONTROLLED STUDY; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; ONCOGENE C MYC; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; TRANSCRIPTION INITIATION; TUMOR CELL; UBIQUITINATION;

ANIMALS; BETA CATENIN; CELL DIVISION; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOSKELETAL PROTEINS; MICE; MICE, NUDE; PROTEIN ENGINEERING; PROTO-ONCOGENE PROTEINS; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; UBIQUITINS; WNT PROTEINS; ZEBRAFISH PROTEINS;

MUS MUSCULUS;

EID: 2542461324     PISSN: 14712199     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2199-4-10     Document Type: Article

References (32)

1. Wodarz A and Nusse R: Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998, 14:59-88.
2. Nusse R and Varmus HE: Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982, 31:99-109.
3. Polakis P: Wnt signaling and cancer. Genes Dev 2000, 14:1837-51.
4. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-90.
5. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-12.
6. Tetsu O and McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422-6.
7. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R and Ben-Ze'ev A: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999, 96:5522-7.
8. Behrens J and Birchmeier W: Cell-cell adhesion in invasion and metastasis of carcinomas. Cancer Treat Res 1994, 71:251-66.
9. Perl AK, Wilgenbus P, Dahl U, Semb H and Christofori G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998, 392:190-3.
10. Hochstrasser M: Ubiquitin-dependent protein degradation. Annu Rev Genet 1996, 30:405-39.
11. Deshaies RJ: SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999, 15:435-67.
12. Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, Andersen JS, Mann M, Mercurio F and Ben-Neriah Y: Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature 1998, 396:590-4.
13. JT Winston, Strack P, Beer-Romero P, Chu CY, Elledge SJ and Harper JW: The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev 1999, 13:270-83.
14. Tan P, Fuchs SY, Chen A, Wu K, Gomez C, Ronai Z and Pan ZQ: Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of I kappa B alpha. Mol Cell 1999, 3:527-33.
15. Latres E, Chiaur DS and Pagano M: The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 1999, 18:849-54.
16. Zhou P, Bogacki R, McReynolds L and Howley PM: Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol Cell 2000, 6:751-6.
17. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E and Polakis P: Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997, 275:1790-2.
18. van de Wetering M, Cavallo R, Dooijes D, van Beest M, van Es J, Loureiro J, Ypma A, Hursh D, Jones T and Bejsovec A et al.: Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 1997, 88:789-99.
19. Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW and Vogelstein B: Identification and classification of p53-regulated genes. Proc Natl Acad Sci U S A 1999, 96:14517-22.
20. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M and Tokino T et al.: AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000, 24:245-50.
21. Hsu W, Shakya R and Costantini F: Impaired mammary gland and lymphoid development caused by inducible expression of Axin in transgenic mice. J Cell Biol 2001, 155:1055-64.
22. Morin PJ, Vogelstein B and Kinzler KW: Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci U S A 1996, 93:7950-4.
23. Shih IM, Yu J, He TC, Vogelstein B and Kinzler KW: The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res 2000, 60:1671-6.
24. Neo SY, Zhang Y, Yaw LP, Li P and Lin SC: Axin-induced apoptosis depends on the extent of its JNK activation and its ability to down-regulate beta-catenin levels. Biochem Biophys Res Commun 2000, 272:144-50.
25. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D and Haramis AP et al.: The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002, 111:241-50.
26. Xu L, Corcoran RB, Welsh JW, Pennica D and Levine AJ: WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev 2000, 14:585-95.
27. Kioussi C, Briata P, Baek SH, Rose DW, Hamblet NS, Herman T, Ohgi KA, Lin C, Gleiberman A and Wang J et al.: Identification of a Wnt/ Dvl/beta-Catenin --> Pitx2 pathway mediating cell-type-specific proliferation during development. Cell 2002, 111:673-85.
28. Davis M, Hatzubai A, Andersen JS, Ben-Shushan E, Fisher GZ, Yaron A, Bauskin A, Mercurio F, Mann M and Ben-Neriah Y: Pseudosub-substrate regulation fo the SCF([beta]-TrCP) ubiquitin ligase by hnRNP-U. Genes Dev 2002, 16:439-451.
29. Chan TA, Wang Z, Dang LH, Vogelstein B and Kinzler KW: Targeted inactivation of CTNNB1 reveals unexpected effects of beta - catenin mutation. Proc Natl Acad Sci U S A 2002, 99:8265-70.
30. Kim JS, Crooks H, Foxworth A and Waldman T: Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors. Mol Cancer Ther 2002, 1:1355-9.
31. Weinstein IB: Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 2002, 297:63-4.
32. D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, Cox JD, Ha SI, Belka GK and Golant A et al.: c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001, 7:235-9.